PDK1 is expressed in ovarian serous carcinoma and correlates with improved survival in high-grade tumors

Anticancer Research

Volumn 35, Issue 11, 2015, Pages 6329-6334

  Lohneis, Philipp ^a   Darb Esfahani, Silvia ^a   Dietel, Manfred ^a   Braicu, Ioana ^a   Sehouli, Jalid ^a   Arsenic, Ruza ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

3 phosphoinositide dependent protein kinase 1; Immunohistochemistry; Intracellular signaling; Serous carcinoma of the ovary

Indexed keywords

PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; CYSTADENOCARCINOMA; ENZYME IMMUNOASSAY; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84946071466     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Kurman RJ: Origin and molecular pathogenesis of ovarian highgrade serous carcinoma. Ann Oncol 24(Suppl 10): x16-21, 2013.
3. Kurman RJ and Shih IM: Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum Pathol 42: 918-931, 2011.
4. May T, Shoni M, Crum CP, Xian W, Vathipadiekal V, Birrer M, Rosen B, Tone A and Murphy KJ: Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles. Gynecol Oncol 128: 488-492, 2013.
5. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P and Pignata S: Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev 41: 136-143, 2015.
6. Nik NN, Vang R, Shih Ie M and Kurman RJ: Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu Rev Pathol 9: 27-45, 2014.
7. Vang R, Shih Ie M and Kurman RJ: Fallopian tube precursors of ovarian low-and high-grade serous neoplasms. Histopathology 62: 44-58, 2013.
8. Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman, DG, Gilks CB, Miller DM and McAlpine JN: The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 10: 296-306, 2012.
9. Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, E Oh, Modi DA, Wei JJ and Burdette JE: Mutant p53 expression in fallopian tube epithelium drives cell migration. Int J Cancer 137: 1528-1538, 2015.
10. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, Michalski CW, Schlitter AM, Esposito I, Kind AJ, Rad L, Schnieke AE, Baccarini M, Alessi DR, Rad R, Schmid RM, Schneider G and Saur D: Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420, 2013.
11. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK and Yu Q: PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 3: 1156-1171, 2013.
12. Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK and Darley RL: The PDK1 master kinase is overexpressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 2013.
13. Bayascas JR, Leslie NR, Parsons R, Fleming S and Alessi DR: Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN+/-mice. Curr Biol 15: 1839-1846, 2005.
14. Flynn P, Wongdagger M, Zavar M, Dean NM and Stokoe D: Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol CB 10: 1439-1442, 2000.
15. Ahmed N, Riley C and Quinn MA: An immunohistochemical perspective of PPAR beta and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumors. Br J Cancer 98: 1415-1424, 2008.
16. Tumors WHOCo: WHO classification, tumors of the breast and female genital organs. 2014.
17. Arsenic R: Immunohistochemical analysis of PDK1 expression in breast cancer. Diagn Pathol 9: 82, 2014.
18. Prat J: Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 460: 237-249, 2012.
19. Najafov A, Shpiro N, and Alessi DR: Akt is efficiently activated by PIF-pocket-and PtdIns(3,4,5)P-3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J 448: 285-295, 2012.
20. Raimondi C, Chikh A, Wheeler AP, Maffucci T and Falasca M: A novel regulatory mechanism links PLCgamma1 to PDK1. J cell Sci 125: 3153-3163, 2012.
21. Raimondi C and Falasca M: Targeting PDK1 in cancer. Curr Med Chem 18: 2763-2769, 2011.
22. Lu Z, Cox-Hipkin MA, Windsor WT and Boyapati A: 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol Cancer Res MCR 8: 421-432, 2010.
23. Huang J, Zhang L, Greshock J, Colligon TA, Wang Y, Ward R, Katsaros D, Lassus H, Butzow R, Godwin AK, Testa JR, Nathanson KL, Gimotty PA, Coukos G, Weber BL and Degenhardt Y: Frequent genetic abnormalities of the PI3K/AKT pathway in in primary ovarian cancer predict patient outcome. Genes, chromosomes & cancer 50: 606-618, 2011.
24. Cancer Genome Atlas Research N: Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
25. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK and Yu Q: PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 3: 1156-1171, 2013.
26. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23: 5853-5857, 2004.
27. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR and Garraway LA: AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21-32, 2009.
28. Bilanges B and Stokoe D: Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem J 388: 573-583, 2005.